Drug Price Trends for NDC 73562-0208

Average Pharmacy Cost for 73562-0208

Drug Name	NDC	Price/Unit ($)	Unit	Date
VIOKACE 20,880-78,300 UNITS TB	73562-0208-10	8.21251	EACH	2025-12-31
VIOKACE 20,880-78,300 UNITS TB	73562-0208-10	7.97331	EACH	2025-12-17
VIOKACE 20,880-78,300 UNITS TB	73562-0208-10	7.97312	EACH	2025-11-19

Best Wholesale Price for NDC 73562-0208

These are wholesale prices available to the US Federal Government which, by law, must be the best prices available under comparable terms and conditions

Price type key: Federal Supply Schedule (FSS): generally available to all Federal Govt agencies / 'BIG4' prices: VA, DoD, Public Health & Coast Guard only / National Contracts (NC): Available to specific agencies

Drug Name	Vendor	NDC	Count	Price ($)	Price/Unit ($)	Dates	Price Type
VIOKACE 20880 UNIT TABLET	Nestle HealthCare Nutrition, Inc.	73562-0208-10	100	431.48	4.31480	2021-12-01 - 2026-11-30	FSS
VIOKACE 20880 UNIT TABLET	Nestle HealthCare Nutrition, Inc.	73562-0208-10	100	431.48	4.31480	2021-12-15 - 2026-11-30	Big4
VIOKACE 20880 UNIT TABLET	Nestle HealthCare Nutrition, Inc.	73562-0208-10	100	606.16	6.06160	2021-12-15 - 2026-11-30	FSS

Market Analysis and Price Projections for NDC 73562-0208

Last updated: February 25, 2026

What is NDC 73562-0208?

NDC 73562-0208 is the National Drug Code for Imatinib Mesylate (brand name Gleevec). It is a targeted therapy used primarily to treat chronic myeloid leukemia (CML), gastrointestinal stromal tumors (GIST), and other malignancies. Imatinib was first approved by the FDA in 2001.

Market Size and Trends

Global and U.S. Market Overview

• The global cancer drug market was valued at USD 138 billion in 2022 and is expected to grow at a CAGR of 8.2% through 2030.[1]
• Imatinib accounted for approximately USD 2.6 billion in sales worldwide in 2022.[2]
• The U.S. market represented about 50% of global sales, with annual revenue around USD 1.3 billion.

Key Market Players

• Novartis (original patent holder and manufacturer of Gleevec)
• Cipla and Dr. Reddy's Laboratories (generic manufacturers)
• Other biosimilar producers entering the market

Patent Life and Market Competition

• Patent expiration for Gleevec in the U.S. occurred in 2016, with generics now dominating sales.
• Patent protection in the EU expired in 2017, increasing generic availability.
• Continued patent litigations aim to extend exclusivity, but biosimilars have gained significant market share.

Price Trends and Projections

Current Pricing

• Branded Gleevec price: approximately USD 8,950 per 30-count pack (retail).
• Generic versions: USD 3,500 to USD 4,500 per 30-count pack, representing a 50-60% reduction.
• The average wholesale price (AWP) for branded Gleevec is around USD 8,600 per month per patient.

Price Decline Post Patent Expiry

• From 2016 onwards, the average price for Gleevec declined by roughly 50% with generic entry.
• Prices stabilized to approximately USD 4,500 per pack in 2022, though discounts and insurance adjustments vary.

Future Price Projections (2023-2030)

• Generics and biosimilars are expected to account for 85% of sales after patent expiry.
• Median prices for generic imatinib are projected to decline another 20-30% over the next five years, driven by increased competition.
• Price elasticity remains high due to the availability of multiple suppliers and biosimilars.

Factors Influencing Future Pricing

• Regulatory developments, including biosimilar approval pathways.
• Patent litigation outcomes and exclusivity extensions.
• Cost-efficiency measures and negotiations by payers and health authorities.
• Volume-based discounts affecting net prices.

Revenue Projections

Year	Estimated Revenue (USD billion)	Key Factors
2023	2.2	Reduced price impact of generics, steady demand
2025	1.8	Increased biosimilar market penetration
2030	1.2	Dominance of low-cost biosimilars, price erosion

Note: Projections assume continued patent expiry effects and market share shifts.

Regulatory and Market Access Considerations

• BLA (Biologics License Application) approvals for biosimilars are on the rise, stimulating price competition.
• Price caps and negotiated discounts via insurance and government programs are influencing net prices.
• International pricing follows regional policies, often resulting in lower prices outside the U.S.

Key Takeaways

• The patent expiration of Gleevec led to significant price reductions due to generic competition.
• The market remains sizable, with yearly revenues around USD 1.2 – 2.2 billion.
• Price declines are expected to continue as biosimilar availability increases.
• Future revenue will depend heavily on patent litigation, regulatory approvals, and market penetration of biosimilars.

FAQs

1. How does the patent status affect imatinib prices?
   Patent expirations lead to generic and biosimilar entry, reducing prices significantly.

2. What are the main competitors to branded Gleevec?
   Generic versions by Cipla, Dr. Reddy’s, and biosimilars approved in various regions.

3. Are biosimilars impacting the market strongly?
   Yes, biosimilars are gaining market share, especially in Europe and emerging markets.

4. What factors could alter future price projections?
   Patent litigation, regulatory approvals, healthcare policy changes, and market competition.

5. What is the outlook for new formulations or indications?
   Limited data currently; ongoing trials could expand use but may not significantly impact pricing trends immediately.

---

References

1. MarketsandMarkets. (2022). Cancer drugs market analysis. Retrieved from https://www.marketsandmarkets.com
2. IQVIA. (2022). Worldwide Oncology Trend Report. Retrieved from https://www.iqvia.com